Phase II trials in patients with carcinoma of unknown primary: A pooled data analysis

Investigational New Drugs

Volumn 28, Issue 2, 2010, Pages 178-184

  Adenis, Antoine ^a   Ferté, Charles ^a   Penel, Nicolas ^a,b  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

Author keywords

Carcinoma of unknown primary; Methodology; Phase II trials; Pooled data analysis; Response rate

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MITOMYCIN C; PACLITAXEL;

ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SAMPLE SIZE; SURVIVAL TIME; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; CONFIDENCE INTERVALS; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; SALVAGE THERAPY;

EID: 77952242533     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9261-5     Document Type: Article

References (37)

1. N Pavlidis 2007 Forty years experience of treating cancer of unknown primary Acta Oncol (Madr) 46 592 601 10.1080/02841860701243095 10.1080/02841860701243095 (Pubitemid 46911913)
2. GR Varadhachary D Talantov MV Raber C Meng KR Hess T Jatkoe, et al. 2008 Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation J Clin Oncol 26 4442 4448 10.1200/JCO.2007.14.4378 10.1200/JCO.2007.14.4378 1:CAS:528:DC%2BD1cXht1ejur%2FF 18802157
3. HM Harlings RK Van Laar JM Kerst HM Helgasar J Wessling JJ Van der Hoeven, et al. 2008 Gene expression profiling to identify the histogenetic origin of metastases adenocarcinoma of unknown primary J Clin Oncol 26 4435 4441 10.1200/JCO.2007.14.6969 10.1200/JCO.2007.14.6969
4. S Culine A Lhortolary JJ Voigt R Bugat C Théodore F Priou MC Kaminisky, et al. 2003 Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French study group on carcinomas of unknown primary (GEFCAPI 01) J Clin Oncol 21 3479 3482 10.1200/JCO.2003.12.104 10.1200/JCO.2003.12.104 1:CAS:528:DC%2BD2cXpsVKjtbw%3D 12972523 (Pubitemid 46594080)
5. S Palmeri V Lorusso L Palmeri M Vaglica C Porta R Nortilli, et al. 2006 Cisplatin and gemcitabine with either vinorelebine or paclitaxel in the treatment of carcinomas of unknown primary Cancer 107 2898 2905 10.1002/cncr.22379 10.1002/cncr.22379 1:CAS:528:DC%2BD2sXovF2itw%3D%3D 17109447 (Pubitemid 44937045)
6. JD Hainsworth DR Spigel C Farley DS Thompson DL Shipley A Greco 2007 Phase II trial of bavacizumab and erlotinib in carcinomas of unknown primary site: the Minne Pearl cancer research network J Clin Oncol 25 1747 1752 10.1200/JCO.2006.09.3047 10.1200/JCO.2006.09.3047 1:CAS:528:DC%2BD2sXlvFyktbk%3D 17470864 (Pubitemid 46797956)
7. KB Pittman IN Olver B Koczwara D Kotsek WK Patterson DM Keefe, et al. 2006 Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide cancer trials and education collaborative study Br J Cancer 2002 95 10 1309 1313 10.1038/sj.bjc.6603440 1:CAS:528:DC%2BD28XhtF2ns7%2FK (Pubitemid 44760078)
8. JD Hainsworth DR Spigel EL Raefsky ME Kuzur K Yost M Kommor, et al. 2005 Combination chemotherapy with gemcitabine in patients with previously treated carcinoma of unknown primary site Cancer 104 1992 1997 10.1002/cncr.21416 10.1002/cncr.21416 1:CAS:528:DC%2BD2MXht1aqs77O 16130138 (Pubitemid 41513185)
9. YH Park BY Ryoo SJ Choi SH Yang HT Kim 2004 A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site Jpn J Clin Oncol 34 681 685 10.1093/jjco/hyh124 10.1093/jjco/hyh124 15613558 (Pubitemid 41615281)
10. FA Greco GI Rodriguez DW Shaffer R Hermann S Litchy DA Yardley, et al. 2004 Carcinoma of unknown primary site: sequential treatment with paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: a Minnie Pearl cancer research network phase II trial Oncologist 9 644 652 10.1634/ theoncologist.9-6-644 10.1634/theoncologist.9-6-644 1:CAS:528: DC%2BD2MXhs1ykuw%3D%3D 15561808 (Pubitemid 39546405)
11. A Piga R Nortilli GL Cetto N Cardelli N Fedelli G Fiorentini, et al. 2004 Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site Br J Cancer 90 1898 1904 10.1038/sj.bjc.6601785 10.1038/sj.bjc.6601785 1:CAS:528:DC%2BD2cXjvValsr8%3D 15138469 (Pubitemid 38746328)
12. D Pouessel S Culine C Becht M Ychou G Romieu M Fabbro, et al. 2004 Gemcitabine and docetaxel s front-line chemotherapy in patients with carcinoma of an unknown primary site Cancer 100 1257 1261 10.1002/cncr.20100 10.1002/cncr.20100 1:CAS:528:DC%2BD2cXivFagtrw%3D 15022294 (Pubitemid 38325954)
13. C Balana JL Manzano I Moreno B Cirauqui A Abad A Font, et al. 2003 A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site Ann Oncol 14 1425 1429 10.1093/annonc/mdg361 10.1093/annonc/mdg361 1:STN:280:DC%2BD3svhsFSjtA%3D%3D 12954583 (Pubitemid 37185290)
14. L Asserhorn AR Norman D Cunningham T Iveson M Seymour T Hickissh, et al. 2003 A randomised study of protracted venous infusion of 5-fluorourcil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary Eur J Cancer 39 1121 1128 10.1016/S0959-8049(03) 00150-3 10.1016/S0959-8049(03)00150-3
15. FA Greco HA Burris S Litchy JH Barton JE Bradaf P Richards, et al. 2002 Gemcitabine, Carboplatin, and Paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl cancer research network study J Clin Oncol 20 1651 1656 10.1200/JCO.20.6.1651 10.1200/JCO.20.6.1651 1:CAS:528:DC%2BD38XivFeitrc%3D 11896116 (Pubitemid 34260547)
16. S Culine M Fabbro M Ychou G Romieu D Cupissol F Pinguet 2002 Alternative bimonthly cycles of doxorubicin, cyclophosphaide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site Cancer 94 840 846 10.1002/cncr.10264 10.1002/cncr.10264 1:CAS:528:DC%2BD38XhsVOju70%3D 11857320 (Pubitemid 34132315)
17. JE Dowell AM Garrett Y Shyr DH Johnson KR Hande 2001 A randomized phase II trial in patients with carcinoma of an unknown primary site Cancer 91 592 597 10.1002/1097-0142(20010201) 91:3<592::AID-CNCR1039>3.0.CO;2-5 10.1002/1097-0142(20010201)91:3<592::AID-CNCR1039>3.0.CO;2-5 1:STN:280:DC%2BD3M7ktFOguw%3D%3D 11169943
18. E Briasoulis H Klofonos D Bafaloukos S Epaminondas G Fountzilas N Xiros, et al. 2000 Carboplatin plus pacliaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study J Clin Oncol 18 3101 3107 1:CAS:528:DC%2BD3cXntVCgsb8%3D 10963638
19. FA Greco JB Erland LH Morrissey HA Burris III RC Hermann R Steis, et al. 2000 Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin Ann Oncol 11 211 215 10.1023/A:1008369812295 10.1023/A:1008369812295 1:STN:280:DC%2BD3c3it1eqtw%3D%3D 10761758 (Pubitemid 30148737)
20. CI Falkson GL Cohen C Mitomycin 1998 Epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin Oncology 55 116 121 10.1159/000011845 10.1159/000011845 1:CAS:528:DyaK1cXotFCjuw%3D%3D 9499185 (Pubitemid 28052255)
21. JD Hainsworth HA Burris III SW Calvert NT Willcutt DC Scullin J Bramham, et al. 2001 Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl cancer research network Cancer Invest 19 335 339 10.1081/CNV-100103127 10.1081/CNV-100103127 1:CAS:528:DC%2BD3MXkvFaqtrs%3D 11405172 (Pubitemid 32525180)
22. JD Hainsworth JB Erlnd LA Kalman MT Schreeder FA Greco 1997 Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide J Clin Oncol 15 2385 2393 1:CAS:528: DyaK2sXkt1ersb8%3D 9196154
23. M Saghatchian K Fizazi C Borel M Ducreux P Ruffié T Le Chevalier, et al. 2001 Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation-results of a prospective study Ann Oncol 12 535 540 10.1023/A:1011129429499 10.1023/A:1011129429499 1:STN:280: DC%2BD3MzjtFamsw%3D%3D 11398889 (Pubitemid 32472111)
24. S Culine M Fabbro M Ychou G Romieu D Cupissol H Pujol 1999 Chemotherapy in carcinomas of unknown primary site : high-dose intensity policy Ann Oncol 10 569 575 10.1023/A:1026478009050 10.1023/A:1026478009050 1:STN:280: DyaK1MzksVCqtA%3D%3D 10416007 (Pubitemid 29305435)
25. E Guardiola X Pivot X Tchicknavorian N Magne J Otto A Thyss, et al. 2001 Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site. A phase II trial Am J Clin Oncol 24 372 375 10.1097/00000421-200108000-00012 10.1097/00000421-200108000-00012 1:STN:280:DC%2BD3MvislSjug%3D%3D 11474265 (Pubitemid 32730732)
26. E Voog Y Merrouche V Trillet-Lenoir C Lasset PY Peaud P Rebattu, et al. 2000 Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary Am J Clin Oncol 23 614 616 10.1097/00000421-200012000-00018 10.1097/00000421-200012000-00018 1:STN:280:DC%2BD3M7gvVKmtg%3D%3D 11202809 (Pubitemid 32429113)
27. BJ Schneider B El-Rayes JH Muler PA Philip GP Kalemkerian KA Griffith, et al. 2007 Phase II trial of carboplatin, gemcitabine, and capeticabine in patients with carcinoma of unknown primary site Cancer 110 770 775 10.1002/cncr.22857 10.1002/cncr.22857 1:CAS:528:DC%2BD2sXhtVajsrbI 17594717 (Pubitemid 47257653)
28. FX Parnis IN Olver D Kotasek J Norman A Taylor J Russell, et al. 2000 Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site Ann Oncol 11 883 884 10.1023/A:1008311919633 10.1023/A:1008311919633 1:STN:280:DC%2BD3cvks1Sntg%3D%3D 10997819
29. W Berry M Elkory M O'Rourke M Kahn L Asmar 2007 Results of a phase II study with weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic? Cancer Invest 25 27 1 10.1080/07357900601130656 10.1080/07357900601130656 1:CAS:528:DC%2BD2sXnt1agsLs%3D 17364554 (Pubitemid 46423583)
30. BF El-Rayes AF Shields M Zalupski LK Heilbrun V Jain D Terry, et al. 2005 A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary Am J Clin Oncol 28 152 156 10.1097/01.coc.0000142590.70472.e2 10.1097/01.coc.0000142590.70472.e2 15803009
31. AG McDonald MC Nicolson LM Samuel AW Hutcheon FY Ahmed 2002 A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site Br J Cancer 86 1238 1242 10.1038/sj.bjc.6600258 10.1038/sj.bjc.6600258
32. E Warner R Goel J Chang W Chow S Verma J Dancey, et al. 1998 A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS) Br J Cancer 77 12 2376 2380 1:CAS:528:DyaK1cXktlCmurk%3D 9649162
33. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 10.1016/0197-2456(89) 90015-9 10.1016/0197-2456(89) 90015-9 1:STN:280:DyaL1M7ps1SjsQ%3D%3D 2702835
34. JA Morris MJ Gardner 1988 Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates BMJ 296 1313 1316 10.1136/bmj.296.6632.1313 10.1136/bmj.296.6632.1313 1:STN:280: DyaL1c3lt1OjsQ%3D%3D 3133061
35. S Gwyther G Bolis M Gore W Ten Bokkel Huinink J Verweij IR Hudson, et al. 1997 Experience with independent radiological review during a Topotecan trial in ovarian cancer Ann Oncol 8 463 468 10.1023/A:1008241127883 10.1023/A:1008241127883 1:STN:280:DyaK2sznsl2htA%3D%3D 9233526 (Pubitemid 27310691)
36. N Penel BN Bui JO Bay D Cupissol I Ray-Coquard S Piperno-Neumann, et al. 2008 Phase II trial of weekly paclitaxel for unresectable angiosarcoma. The ANGIOTAX study J Clin Oncol 26 5269 5274 10.1200/JCO.2008.17.3146 10.1200/JCO.2008.17.3146 1:CAS:528:DC%2BD1cXhsVyqsrbJ 18809609
37. N Penel A Adenis 2009 Publication biases and phase II investigating anticancer targeted therapies Invest New Drugs 27 3 287 88 10.1007/s10637-008- 9186-4 18931825